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  22 
Abstract 23 
Regulatory science underpins the objective evaluation of medicinal products. It is therefore imperative 24 
that regulatory science and expertise remain at the cutting-edge so that innovations of ever-increasing 25 
complexity are translated safely and swiftly into effective, high-quality therapies. We undertook a 26 
comprehensive examination of the evolution of science and technology impacting on medicinal 27 
product evaluation over the next 5-10 years and this horizon-scanning activity was complemented by 28 
extensive stakeholder interviews, resulting in a number of significant recommendations. Highlighted 29 
in particular was the need for expertise and regulatory science research to fill knowledge gaps in both 30 
more fundamental, longer-term research, and with respect to technological and product-specific 31 
challenges. A model is proposed to realise these objectives in Europe, comprising a synergistic 32 
relationship between the European Medicines Agency (EMA), the European Medicines Regulatory 33 
Network and academic research centres to establish a novel regulatory science and innovation 34 
platform. 35 
 36 
What is already known about this subject? 37 
The EMA and medicinal product regulators around the world, are confronted continuously with 38 
advances in science and technology. However, the complexity of innovation is increasing rapidly, 39 
requiring regulatory science to evolve in tandem and to develop an effective mechanism to do so in a 40 
timely manner.  41 
 42 
What this study adds? 43 
This study explores regulatory science needs over the next 5-10 years and proposes a mechanism to 44 
enable regulatory science to keep pace with innovation. 45 
 46 
  47 
Introduction 48 
Translating fundamental science into patient-accessible therapies requires application of diverse 49 
scientific disciplines. Regulatory science underpins the objective evaluation of the safety, efficacy and 50 
quality of medicinal products and crucially informs the regulatory decision-making process.  51 
Specifically, therefore, regulatory science must provide medicines’ regulators with the knowledge to 52 
apply innovative research and novel methodological tools to the objective determination of the 53 
benefits and risks associated with the use of a new medicinal product1.  It is fair to say, however, that 54 
rapid progress in the biomedical and related sciences – for example, in areas such as cell-based 55 
therapies, drug-device combinations, predictive toxicology and artificial intelligence – mean that the 56 
most challenging regulatory questions2-4 are originating from the fastest moving and most competitive 57 
scientific disciplines5. As a result, it is absolutely imperative that regulatory science remains at the 58 
cutting edge so that innovations of ever-increasing complexity are translated safely into efficacious 59 
and affordable therapies in a timely fashion, promoting public health. 60 
The European Medicines Agency (EMA) engages continuously with advances in regulatory science and, 61 
in 2017, undertook a comprehensive baseline review examining the evolution of science and 62 
technology that will impact its core business of medicinal product evaluation over the next 5-10 years.  63 
This horizon-scanning activity was complemented by an extensive stakeholder outreach exercise 64 
across individuals and organisations involved in the entire medicine development lifecycle (and 65 
included, inter alia, the pharmaceutical industry, health technology assessors and payers, regulatory 66 
science experts, academia, scientific organisations and societies, European Union research 67 
infrastructure networks, healthcare professionals and patient representative groups).  The cumulative 68 
result of this concerted effort was a document6, “EMA Regulatory Science to 2025 – Strategic 69 
Reflection”, currently released for public consultation at the end of 2018 and recently summarised in 70 
the literature7. A key component of this reflection is a proposed model to strengthen regulatory 71 
science and innovation in Europe, the elaboration of which is now described6.  72 
 73 
  74 
Methods 75 
1. Horizon scan (baseline review) 76 
The initial (>60) areas of review (see Supplementary Information, Table S1) across health, science, 77 
technology and regulatory science were selected by the EMA’s internal scientific leadership, the 78 
Scientific Coordination Group (SCG). Subsequently, a multidisciplinary research group conducted an 79 
initial horizon scanning exercise. This included mining, inter alia, internal databases and the relevant 80 
scientific literature. In each area reviewed, the state-of-play and the projected opportunities and 81 
challenges over the coming 5-10 years were identified.  These results were authenticated within the 82 
research group, and then peer-reviewed by in-house experts and the SCG. 83 
2. Stakeholder interviews 84 
Interviews were then carried out with external experts and key opinion leaders from the EMA’s 85 
principal stakeholder groups to validate the internal conclusions. Interviewees were nominated by the 86 
European Medicines Regulatory Network (EMRN) and drawn from the Agency’s expert database; non-87 
response error was mitigated through follow-up reminders. The interviews (n = 70) were either semi-88 
structured (55) or open (15). The stakeholders were provided with a series of key questions 89 
(developed by the research group) and an introduction to the baseline review prior to the interviews. 90 
The questions were aligned with the aims of the regulatory science reflection and were trialled with 91 
colleagues, and re-ordered and optimised in terms of timing. The resultant draft script was then tested 92 
on an initial panel of interviewees for feedback. This feedback was incorporated into a final master 93 
script7 targeted towards semi-structured interviews with each stakeholder group. For the open 94 
interviews, the script was used after the interviewees had provided their unprompted, initial topics 95 
for discussion.  96 
3. Data acquisition and analysis 97 
The semi-structured interviews lasted around 1 hour, the open interviews up to 2 hours.  A written 98 
record of the interviews was made by two or more of the research team and then cross-checked for 99 
accuracy and consistency. Analysis of the information obtained involved open and axial coding8,9 100 
whereby the research team attributed codes to meaningful sections of text (words, statements and 101 
sentences). These codes were compared and a subset agreed before undertaking additional rounds 102 
of axial coding. The findings were eventually reported using Consolidated Criteria for Reporting 103 
Qualitative Research (COREQ)10. Finally, the codes were grouped into themes, which were compared 104 
to and merged with the results of the horizon scan and baseline review. From this exercise, a set of 105 
overarching strategic goals for regulatory science emerged along with a number of core 106 
recommendations and associated underlying actions necessary to achieve these aims. 107 
 108 
  109 
Results 110 
The baseline review, horizon scan and stakeholder outreach resulted in over 600 comments and 111 
recommendations.  Many of these identified the need for expertise and regulatory science research 112 
to fill knowledge gaps in two broad areas as discussed in detail in the published EMA document, “EMA 113 
Regulatory Science to 2025 – Strategic reflection”6 and summarised elsewhere7: (i) those requiring 114 
more fundamental, longer-term research, and (ii) where technology or product-specific challenges 115 
were evident. Relatedly, the limited funds available for regulatory science research, and the clear need 116 
for more resource in this area, represented very strong signals.  117 
Regarding expertise, a deficit in the area of regulatory science know-how was identified, particularly 118 
in rapidly evolving domains of research and innovation6 such as drug-device combinations, predictive 119 
toxicology and artificial intelligence. A more proportionate approach to access international expertise 120 
was a recurring suggestion in this regard. Enhanced training in the relevant science for stakeholders 121 




















The primary role of medicines regulatory agencies may be summarised as one of protecting and 142 
promoting public health and, increasingly, by catalysing and enabling science to be translated into 143 
patient-centred healthcare1.  To meet these objectives, the regulatory agency must understand the 144 
fundamentals of the relevant science, and their application in the medicinal product review and 145 
approval process, and be critically informed of key areas of scientific innovation that have the 146 
potential to impact on its core business5,6.  147 
A model to underpin regulatory science and innovation in Europe 148 
A mechanism with which these goals can be achieved in Europe is a synergistic relationship between 149 
the EMA, the EMRN and distributed academic research centres to establish a novel science and 150 
innovation platform – provisionally termed the Regulatory Science and Innovation Programme for 151 
Europe (ReScIPE) – that undertakes both long-term, fundamental research in strategic areas of 152 
regulatory science (Figure 1, upper panel), and shorter-term investigations to address emerging 153 




Figure 1: Upper panel - An iterative partnership between regulators, European public funding agencies 158 
and academic scientists to strategically focus basic research in regulatory science. The potential 159 
funding agencies include those at the European level, such as DG RTD and IMI, and national funders. 160 
Lower panel - Research collaboration between network scientists and academia to tackle rapidly-161 
evolving regulatory science questions and to translate innovation efficiently into regulatory tools and 162 
processes. 163 
ReScIPE: goals and deliverables 164 
It is anticipated that ReScIPE will identify research priorities that promote the field of regulatory 165 
science - including innovative research, development of regulatory tools, education, and scientific 166 
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EMA and the European Medicines 
Regulation Network directly finance 
short-term (< 2 years) research projects
EMA and the European Medicines 
Regulation Network articulate emerging 
regulatory science research challenges
exchange - together with not-for-profit and commercial entities striving to produce safe, effective, 167 
affordable and high-quality medical products. Self-evidently, collaboration involving ReScIPE and the 168 
European pharmaceutical, biotechnology, and high-tech industries is particularly important to the 169 
long-term aims articulated above. With the governance of these collaborations being carefully 170 
decided by funders at the call stage. It is also envisaged that partnerships between EMA, the EMRN 171 
and academia will also develop regulatory training modules and undertake horizon scanning in 172 
emerging areas of innovation, and that ReScIPE will drive a data-sharing culture to foster open science 173 
that is mutually beneficial for all stakeholders. 174 
Precedence for success in Europe 175 
Given the strength of the pharmaceutical and biotechnology industries in Europe, the established 176 
importance of leading scientific professional societies (such as EUFEPS, the European Federation for 177 
Pharmaceutical Scientists), the considerable regulatory expertise at EMA and across the EMRN, and 178 
the world-leading quality of biomedical research related to medical product innovation and 179 
development in European universities and research centres, the present situation also affords a real 180 
opportunity to accomplish a paradigm-shift in regulatory science and innovation through the 181 
establishment of ReScIPE6.  This concept must build upon precedents at the national level, including 182 
the Dutch Medicines Evaluation Board (MEB) Regulatory Science Program, which has led to the 183 
creation of a broad network of partnerships between academic and other external parties11. In this 184 
way, MEB has committed a budget to catalyse and facilitate both short-term projects and longer-term 185 
PhD theses to enhance its ability to deliver high quality benefit/risk assessment.  Three specific areas 186 
of the medicinal product lifecycle have been targeted:  development and innovation, regulation and 187 
decision-making, and consumer use and safety.  At the same time, MEB is actively participating in 188 
regulatory education and learning, for example, via internships to bachelor- and masters-level 189 
students.  Other similar research models include Germany’s Federal Institute for Drugs and Medical 190 
Devices (BfArM)12, which conducts research in collaboration with national, EU and international 191 
research centres and academia, and the Paul-Ehrlich-Institut, (PEI)13, which interacts with leading 192 
research institutes, academia and international organisations to set new standards in the field of 193 
vaccines/biomedicines.  Another example is the European Center of Pharmaceutical Medicine 194 
(ECPM)14, based at the University of Basel, that provides training which covers the entire medicinal 195 
product development process from molecule identification to commercialisation, including an 196 
understanding of essential aspects of regulatory science.  197 
Most recently, a new EU-funded project entitled “Strengthening Training of Academia in Regulatory 198 
Science” (STARS)15, was initiated. The consortium involved includes the EMA and 20 regulatory bodies. 199 
The three-year project aims to analyse and improve the training of academia in regulatory science and 200 
to enhance regulatory protocol assistance in academic-driven health research. These measures are 201 
designed to facilitate translational clinical research in academia, and to accelerate the availability of 202 
innovative, cutting-edge therapies to patients across Europe.  203 
CERSIs: an American model 204 
Furthermore, evidence from the US, in particular, suggests that this model of synergistic partnership 205 
between a regulatory agency, academic researchers and key stakeholders, such as established 206 
pharmaceutical companies and small and/or medium-sized enterprises, is a fruitful approach to 207 
ensure that research ideas are effectively translated into new and effective medical products and that 208 
technological advances resulting in novel tools are applied to catalysing and facilitating the regulatory 209 
review and approval process, thereby accelerating patient access to innovative therapies16. The US 210 
Food & Drug Administration (FDA) currently funds five Centres of Excellence in Regulatory Science & 211 
Innovation, each with a particular focus associated with the Agency’s priority areas17. The UCSF-212 
Stanford Centre, for example, is addressing the over-arching strategic aim to develop new models and 213 
methods for moving drugs and other medical products, such as devices and cell-based therapies, from 214 
the laboratory to clinical trials18. In parallel, the Centre provides training and educational programs 215 
(including internships and laboratory rotations) for PhD students, postdoctoral fellows, faculty and 216 
scientists in the industry and at the FDA. 217 
Conclusions 218 
Scientific challenges in regulatory science and innovation span the entire spectrum of the medicinal 219 
product lifecycle – for both human and veterinary drug product development19 – from, for example, 220 
the conception and development of new cell-based treatments, through new thinking in predictive 221 
toxicology, and the rapidly increasing variety of imaginative drug-device combination products, to new 222 
ideas concerning the personalisation and precision of medical therapy (including the manufacturing 223 
challenges)5,6.  As such, there is a strong rationale for ReScIPE to use a distributed model, and to 224 
benefit from the collaboration of expertise across different academic centres that each concentrate 225 
on specific target areas of investigation. 226 
The scale of investment required is logically a function of the number and complexity of the 227 
transformational research questions to be addressed, the requirements for associated infrastructure, 228 
and the perspective taken on the specific role of ReScIPE in training early-career scientists in this 229 
important field. In developing existing interactions between the EMA, the EMRN and academia (as 230 
well as integrating with ongoing key European activities as mentioned above) to ensure that 231 
regulatory science keeps up-to-date, these resources must also be proportional to the public health 232 
aim of ensuring that medicines’ regulation not only guarantees safe and effective therapies that meet 233 
the highest standards of quality, but that it also facilitates patient access to these innovative and 234 
important medicines6.  While this latter challenge is one with which regulators are wrestling to an 235 
ever-increasing extent, further discussion of how to achieve better and more uniform access to novel 236 
(and almost always expensive) therapies, and to a high standard of healthcare in general, is beyond 237 
the scope of this article.   238 
 239 
 240 
Disclaimer: The views expressed in this article are the personal views of the authors and may not be 241 
understood or quoted as being made on behalf of or reflecting the position of the agencies or 242 
organizations with which the authors are affiliated. 243 
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